Loading...
Market
What will be the next major legislative action related to Chinese biotech firms by December 31, 2024?
2
Jim McGovern•Massachusetts•House Rules Committee•Biosecure Act•Chinese•WuXi Biologics•BGI•McGovern•China•American•Chinese Communist Party•House of Representatives
Resolution / Starting Odds
New Legislation Introduced • 25%
Existing Legislation Amended • 25%
No Action Taken • 25%
Other • 25%
Official records from the U.S. Congress
Story
Rep. Jim McGovern Opposes Biosecure Act on National Security Grounds, Targeting WuXi Biologics and BGI
Sep 9, 2024, 07:02 PM
Rep. Jim McGovern of Massachusetts, the ranking member on the House Rules Committee, has announced his opposition to the Biosecure Act on national security grounds. This legislation aims to restrict business with Chinese biotech firms, including WuXi Biologics and BGI, on national security grounds. McGovern's stance has stirred controversy, given his history as a China human-rights advocate. The bill is part of a broader legislative push by U.S. lawmakers to counter China's influence, with other measures targeting Chinese military-linked companies and addressing issues such as data theft and economic competition. The Biosecure Act is seen as critical for protecting American genetic data from the Chinese Communist Party's ambitions in biotechnology. The House of Representatives is expected to vote on the bill this week.
View original story
Similar markets
BGI Group • 25%
China National GeneBank • 25%
Beijing Genomics Institute • 25%
Other • 25%
Yes • 50%
No • 50%
Reimpose sanctions on ViaSat • 25%
Impose sanctions on another US defense company • 25%
Announce new trade agreements with US defense companies • 25%
No significant action • 25%
Yes • 50%
No • 50%
New sanctions • 25%
Another botnet disruption • 25%
Public indictment of Chinese nationals • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lift Bitcoin ban • 25%
Stricter regulations • 25%
No changes • 25%
Other • 25%
New sanctions by the US on China • 25%
New sanctions by China on US defense companies • 25%
New trade agreements involving defense companies • 25%
No significant action • 25%
